v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net revenue $ 8,613 $ 5,004
Net operating costs and expenses:    
Cost of revenue 4,447 1,384
Research and development 3,210 2,456
Selling, general and administrative 31,033 28,060
Intangible amortization 2,092 1,002
Total net operating costs and expenses 40,782 32,902
Loss from operations (32,169) (27,898)
Other (income) expense, net:    
Gain on warrant derivative liabilities (25,709) (10,409)
Loss on compound derivative of Scilex-St. James Loans 21,829 0
Change in fair value of debt and liability instruments 2,797 6,114
Other expense, net 3,779 2,481
(Gain) Loss on foreign currency exchange 279 (4)
Unrealized loss on digital assets, net 18,064 0
Unrealized (gain) on equity method investments carried at fair value, net 31,710 0
Realized (gain) on equity method investments carried at fair value, net (42,338) 0
Realized loss on securities 3,071 0
Total other (income) expense, net 13,481 (1,818)
Loss before income taxes (45,650) (26,080)
Net loss (45,650) (26,080)
Net income attributable to noncontrolling interests (2,380) 0
Net loss attributable to common stockholders $ (43,270) $ (26,080)
Net loss per share attributable to common stockholders - basic and diluted    
Loss per share attributable to common stockholders - basic $ (6.28) $ (2.26)
Loss per share attributable to common stockholders - diluted $ (6.28) $ (2.26)
Weighted average number of shares during the period basic & diluted    
Weighted average number of shares during the period-basic 6,891 11,565
Weighted average number of shares during the period -diluted 6,891 11,565
Comprehensive loss:    
Net loss attributable to common stockholders $ (43,270) $ (26,080)
Other comprehensive income:    
Foreign currency translation adjustment (747) 0
Total other comprehensive income (747) 0
Comprehensive loss attributable to common stockholders $ (44,017) $ (26,080)